📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-10-01 20:05
122 analysed today
FollowTelegram
122
Today
149,523
All-time analysed
42,890
Positive
6,652
Negative
91,308
Neutral
8,605
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
16 announcements match the current filters (relevance ≥ 5).
Syncom Formulations Shareholders Approve Appointment of Rahul Bankda as MD
Syncom Formulations (India) Limited announced shareholder approval at its 38th AGM held on September 30, 2026, for key leadership appointments. Shri Rahul Vijay Bankda has been appointed as Managing Director, effective retroactively from August 12, 2026. Additionally, Smt. Rinki Ankit Bankda was appointed as Whole Time Director effective August 12, 2026, and Smt. Ruchi Jindal was re-appointed as Woman Independent Director for a 5-year term from June 28, 2027.
Confidence: HIGH
What changedFormal shareholder confirmation of Rahul Vijay Bankda as Managing Director and Rinki Ankit Bankda as Whole Time Director, effective August 12, 2026.
Why it mattersConfirms internal succession and board leadership stability within the promoter group for managing ongoing business operations.
AGM Date: 30th September, 2026Effective Appointment Date: 12th August, 2026Independent Director Term Extension: 5 consecutive years
📅 Short termNeutral procedural confirmation of management roles already implemented in August 2026; no material stock impact expected.
📈 Long termEnsures leadership stability and continuity in governance across the company's formulation business.
⚠ Risk flags
- Promoter-concentrated executive leadership with close family relationships among top directors.
Key Highlights
Shareholders approved the appointment of Rahul Vijay Bankda as Managing Director effective August 12, 2026
Appointment of Rinki Ankit Bankda as Whole Time Director confirmed effective August 12, 2026
Re-appointment of Ruchi Jindal as Independent Director approved for a 5-year term ending June 27, 2032
AGM concluded on September 30, 2026, confirming decisions originally effected on August 12, 2026
👀 What to Watch
Monitor upcoming quarterly results to observe strategic continuity under the confirmed leadership team. Track whether the ongoing expansion efforts translate to steady margin performance.
Promoters Waive ₹4.75 Cr Final FY26 Dividend; Net Outgo Halved to ₹4.65 Cr
Syncom Formulations announced that its Promoters and Promoter Group have voluntarily and unconditionally waived their entitlement to the proposed final dividend of ₹0.10 per share for FY26. Of the total 94,00,00,000 equity shares, promoters hold 47,53,47,599 shares (approx. 50.57%), resulting in a waiver of ₹4.75 crore. Consequently, the total dividend payout will decrease from ₹9.40 crore to ₹4.65 crore, preserving cash within the business. The dividend remains subject to shareholder approval at the upcoming AGM.
Confidence: HIGH
What changedPromoters have waived their share of the FY26 final dividend, reducing the cash outflow for the dividend by ₹4.75 crore.
Why it mattersThe company retains ₹4.75 crore in internal cash reserves while ensuring public shareholders still receive their ₹0.10 per share distribution.
Dividend per share: ₹0.10Total shares outstanding: 94,00,00,000Promoter shares waived: 47,53,47,599Dividend amount waived: ₹4,75,34,759.90Net final dividend payable: ₹4,64,65,240.10
📅 Short termMarginally positive sentiment for retail investors who receive their full dividend entitlement while the company retains ~50.6% of the budgeted cash outflow.
📈 Long termLimited; reflects promoter alignment and incremental cash retention, but total savings of ₹4.75 crore are modest relative to overall net worth.
Key Highlights
Promoters holding 47,53,47,599 equity shares voluntarily waived final dividend entitlement
Proposed final dividend of ₹0.10 per equity share (face value ₹1 each) for FY26
Total dividend commitment drops from ₹9,40,00,000 to ₹4,64,65,240.10
Waiver amount retained by the company stands at ₹4,75,34,759.90 without consideration
Net dividend to be distributed across 46,46,52,401 public equity shares
👀 What to Watch
Track shareholder voting on the final dividend resolution at the upcoming AGM and monitor how the retained capital is deployed towards ongoing operations or capacity.
58% PAT Growth to ₹24.85 Cr in Q1 FY27; ₹0.10 Dividend Recommended
Syncom Formulations reported a strong Q1 FY27 with Profit After Tax (PAT) rising 58% YoY to ₹24.85 crore, significantly outpacing revenue growth. Total income for the quarter reached ₹133.36 crore, up 8% from ₹122.94 crore in the previous year. The company demonstrated sharp margin expansion, with Profit Before Tax (PBT) surging 59% to ₹32.25 crore. Additionally, the board recommended a final dividend of ₹0.10 per share for FY26, reflecting a 10% payout on face value.
Confidence: HIGH
What changedThe company achieved a significant jump in profitability and margins in Q1 FY27 compared to the same period last year, despite relatively modest top-line growth.
Why it mattersThe results indicate strong operating leverage and successful brand positioning in high-margin segments like IVF and Gynaecology, where its Ovafresh brands are leaders.
Q1 PAT Growth: 58%Q1 Revenue: ₹125.53 crPBT Margin: 24.2%Dividend per share: ₹0.10Q1 Revenue vs TTM Revenue: ~1.0%
📅 Short termThe stock is likely to react positively to the sharp earnings beat and the dividend recommendation in the coming days.
📈 Long termThe company's focus on an ethical, prescription-led model and expansion into specialized domestic divisions provides a structural growth path, though it remains a small-cap player in a competitive market.
⚠ Risk flags
- Heavy reliance on Pharma segment (98.8% of revenue)
- Vulnerability to API price spikes affecting production costs
Key Highlights
Profit After Tax (PAT) increased 58% YoY to ₹24.85 crore from ₹15.75 crore.
Profit Before Tax (PBT) rose 59% YoY to ₹32.25 crore, representing a 24.2% margin.
Revenue from operations grew 7% YoY to ₹125.53 crore.
Recommended a final dividend of ₹0.10 per equity share for the financial year ended March 31, 2026.
Maintains a pan-India field force of over 1,000 medical representatives across 6 specialized divisions.
👀 What to Watch
Monitor the sustainability of the improved 24.2% PBT margin in upcoming quarters and track the progress of the commercial property acquisition from HDFC Bank intended for infrastructure expansion.
Resignation of Whole-Time Director Kedarmal Shankarlal Bankda Effective August 11, 2026
Syncom Formulations (India) Limited has announced the resignation of Mr. Kedarmal Shankarlal Bankda (DIN: 00023050) from his position as Whole-Time Director, effective August 11, 2026. The resignation letter was received by the company on August 8, 2026, at 10:35 AM. The company stated the departure is intended to facilitate timely succession planning and to allow the director to focus on health and well-being. This change occurs as the company manages a TTM revenue of ₹12,539 cr and maintains a high ROCE of 27.0%.
Confidence: HIGH
What changedMr. Kedarmal Shankarlal Bankda has stepped down as a Director and Whole-Time Director of the company.
Why it mattersAs a Whole-Time Director, his departure is significant for executive leadership; however, the company has framed this as a planned succession to ensure an orderly transition of responsibilities.
Effective Date of Resignation: August 11, 2026TTM Revenue: ₹12,539 crMarket Capitalization: ₹30,164 crPharma Segment Growth (YoY): 30.5%Promoter Holding: 50.57%
📅 Short termThe market is likely to view this as a routine management transition given the explicit mention of succession planning and health reasons.
📈 Long termThe long-term impact depends on the quality of the successor and their ability to maintain the current 15.1% operating profit margins and high growth rates.
⚠ Risk flags
- Key management personnel transition
- High reliance on Pharma segment (98.8% of revenue)
Key Highlights
Resignation of Whole-Time Director effective from August 11, 2026
Resignation letter received by the company on August 8, 2026, at 10:35 AM
Company reports TTM revenue of ₹12,539 cr and TTM PAT of ₹1,720 cr
Pharma segment currently contributes 98.8% of total company revenue
Promoter holding remains stable at 50.57% as of June 2026
👀 What to Watch
Investors should monitor the company's upcoming announcements regarding the appointment of a new Whole-Time Director to ensure leadership continuity in the core pharmaceutical formulations segment.
Resignation of Whole-Time Director Kedarmal Shankarlal Bankda Effective August 11, 2026
Syncom Formulations (India) Limited has announced the resignation of Mr. Kedarmal Shankarlal Bankda from his position as Whole-Time Director, effective August 11, 2026. The resignation, received on August 8, 2026, is attributed to succession planning, health considerations, and ensuring an orderly transition of leadership. Given the company's significant market capitalization of Rs 30,164 crore and TTM revenue of Rs 12,539 crore, this leadership change is notable for maintaining operational continuity. The company is currently experiencing strong growth, with its core Pharma segment growing at 30.5% YoY.
Confidence: HIGH
What changedMr. Kedarmal Shankarlal Bankda has stepped down as Whole-Time Director to facilitate succession planning and focus on health.
Why it mattersLeadership transitions in a company of this scale (Rs 30,164 Cr market cap) are critical for maintaining the strategic momentum of its high-growth pharmaceutical formulations business.
Effective Date of Cessation: August 11, 2026Market Capitalization: Rs 30,164 CrTTM Revenue: Rs 12,539 CrPromoter Holding: 50.57%TTM PAT: Rs 1,720 Cr
📅 Short termThe stock price may see neutral to slightly cautious movement as the market processes the exit of a key director and awaits news on a successor.
📈 Long termThe long-term impact depends on the effectiveness of the succession plan and whether the new leadership can sustain the current 27% ROCE and expansion plans.
⚠ Risk flags
- Succession risk
- Potential loss of institutional knowledge
Key Highlights
Resignation of Whole-Time Director effective from August 11, 2026
Resignation letter was received by the company on August 8, 2026, at 10:35 AM
Company maintains a large market capitalization of Rs 30,164 crore
TTM Revenue stands at Rs 12,539 crore with a 15.1% operating margin
Promoter holding remains stable at 50.57% as of June 2026
👀 What to Watch
Investors should monitor the company's upcoming announcements regarding the appointment of a successor to ensure leadership continuity and track if the 28% expected growth rate remains on target.
Syncom Formulations Announces Major Leadership Succession; New MD and CFO Appointed
Syncom Formulations has implemented a comprehensive leadership transition effective August 12, 2026, as part of a planned succession strategy. Shri Rahul Vijay Bankda, who has 23 years of experience and previously served as CFO, has been elevated to Managing Director. Simultaneously, Shri Ankur Vijay Bankda, also with 23 years of experience, has been appointed as the new Chief Financial Officer. These changes follow the resignations of the outgoing Managing Director and Whole-time Director, ensuring the next generation of the promoter group takes over key executive functions.
Confidence: HIGH
What changedA generational shift in the promoter-led management team, with new appointments for the Managing Director, CFO, and Whole-time Director roles.
Why it mattersLeadership continuity is vital for the company's expansion plans and maintaining its 15.1% operating margins. The transition appears orderly and involves internal family members with significant tenure.
New MD Experience: 23 yearsNew CFO Experience: 23 yearsPromoter Holding: 50.57%TTM Revenue: ₹12539 Cr
📅 Short termThe market is likely to view this as a routine succession; no immediate impact on stock price is expected unless strategic shifts are announced.
📈 Long termThe transition to a younger leadership team with decades of internal experience suggests a focus on long-term stability and scaling the core pharma formulations business.
⚠ Risk flags
- Key person risk during transition
- Concentration of key roles within the promoter family
Key Highlights
Shri Rahul Vijay Bankda appointed as Managing Director, bringing 23 years of diversified business experience
Shri Ankur Vijay Bankda appointed as Chief Financial Officer with 23 years of experience in financial management
Smt. Rinki Ankit Bankda appointed as Whole-time Director with 13 years of professional experience
Resignation of Shri Vijay Shankarlal Bankda (MD) and Shri Kedarmal Shankarlal Bankda (WTD) effective August 11, 2026
Reappointment of Smt. Ruchi Jindal as Woman Independent Director for a term starting June 29, 2027
👀 What to Watch
Investors should monitor if the new leadership maintains the company's current growth trajectory (30.5% YoY in Pharma) and high ROCE of 27.0%.
Syncom Formulations Q1 Net Profit Jumps 56% YoY to ₹24.59 Cr
Syncom Formulations (India) Limited reported a strong start to FY27 with a 56.3% YoY increase in Net Profit to ₹24.59 Cr for the quarter ended June 30, 2026. While revenue from operations grew a modest 7% YoY to ₹124.66 Cr, the company achieved significant margin expansion, with Profit Before Tax (PBT) margins rising to 24.1% from 16.5% in the year-ago period. The core Pharmaceuticals segment remains the primary driver, contributing over 99% of total segment revenue. Additionally, the company restated its EPS for prior periods to comply with Ind AS 33, shifting from a Total Comprehensive Income-based to a Profit After Tax-based calculation.
Confidence: HIGH
What changedThe company reported a sharp increase in profitability and margin expansion for Q1 FY27, alongside a technical restatement of its EPS calculation methodology to align with Ind AS 33.
Why it mattersThe significant jump in net profit despite single-digit revenue growth indicates improved operational efficiency and potentially better product mix or pricing power in the core formulations business.
Q1 Net Profit: ₹24.59 CrQ1 Revenue from Operations: ₹124.66 CrPBT Margin: 24.1%Pharma Segment Revenue: ₹131.36 CrRestated EPS (Q1): ₹0.26
📅 Short termThe stock is likely to react positively in the short term due to the substantial bottom-line growth and margin improvement exceeding revenue growth rates.
📈 Long termThe company's ability to maintain high margins in the competitive generic drug market and successfully scale its Pithampur manufacturing operations will be critical for long-term value creation.
⚠ Risk flags
- High revenue concentration in the Pharmaceuticals segment (99%)
- Sensitivity to API price fluctuations which could impact currently expanded margins
Key Highlights
Net Profit increased by 56.3% YoY to ₹24.59 Cr from ₹15.73 Cr in Q1 FY26.
Revenue from operations grew 7% YoY to ₹124.66 Cr compared to ₹116.55 Cr in the previous year.
PBT margin expanded significantly to 24.1% in Q1 FY27 from 16.5% in Q1 FY26.
Pharmaceuticals segment revenue reached ₹131.36 Cr, accounting for 99.1% of total segment revenue.
Restated EPS for Q1 FY27 stands at ₹0.26, up from ₹0.17 in the corresponding quarter last year.
👀 What to Watch
Investors should monitor the sustainability of these expanded margins in the pharmaceutical segment and watch for updates regarding the operationalization of the commercial property acquired from HDFC Bank to support growth.
Rs 0.10 Dividend: Syncom Formulations Sets September 23, 2026, as Record Date
Syncom Formulations (India) Limited has fixed September 23, 2026, as the record date for a final dividend of Rs 0.10 per equity share (10% of face value) for FY 2025-26. The dividend is subject to shareholder approval at the 38th Annual General Meeting (AGM) scheduled for September 30, 2026. The company reported a TTM PAT of Rs 1,720 Cr, and the proposed dividend represents a yield of approximately 0.69% at the current price of Rs 14.5. Uniquely, the company has provided a dividend waiver option for shareholders until September 26, 2026.
Confidence: HIGH
What changedThe company has established the formal timeline for its annual dividend distribution and shareholder meeting for the 2025-26 financial year.
Why it mattersWhile the dividend yield is modest at ~0.69%, the payout confirms the company's ability to distribute profits despite its focus on high growth (28% expected) and infrastructure expansion.
Dividend per share: Rs 0.10Record Date: 23-Sep-2026Dividend Yield: ~0.69%TTM PAT: Rs 1,720 CrAGM Date: 30-Sep-2026
📅 Short termThe stock is likely to trade flat to slightly positive leading up to the ex-dividend date, though the small dividend amount typically limits price volatility.
📈 Long termLimited structural impact from this routine filing; the long-term value depends on the company's ability to maintain its 15.1% OPM and scale its pharma formulations business.
Key Highlights
Final dividend declared at Rs 0.10 per equity share of Rs 1/- each (10% payout).
Record date for determining dividend entitlement is Wednesday, September 23, 2026.
38th Annual General Meeting (AGM) to be held via video conferencing on September 30, 2026.
Shareholders wishing to waive dividend entitlement must submit forms by September 26, 2026.
Company maintains a strong financial position with TTM revenue of Rs 12,539 Cr and minimal debt of Rs 1 Cr.
👀 What to Watch
Investors should ensure their holdings are in their demat accounts by the record date of September 23, 2026, to be eligible for the dividend. Monitor the AGM proceedings on September 30 for updates on the Pithampur manufacturing setup and the HDFC Bank property acquisition.
₹0.10 Final Dividend: Syncom Formulations Sets September 23 as Record Date
Syncom Formulations has recommended a final dividend of ₹0.10 per equity share for FY 2025-26, representing a 10% payout on the face value of ₹1. The company has fixed September 23, 2026, as the record date to determine eligible shareholders. This payout follows a strong financial year where TTM PAT reached ₹1,720 Cr with an EPS of ₹0.89. The dividend is subject to approval at the 38th Annual General Meeting scheduled for September 30, 2026.
Confidence: HIGH
What changedThe company has officially announced the record date and AGM schedule for its FY26 final dividend distribution.
Why it mattersThe announcement confirms the company's ability to maintain shareholder payouts despite a -17.9% 12-month price return, though the absolute dividend yield remains low at approximately 0.69%.
Dividend per share: ₹0.10Record Date: September 23, 2026Dividend vs TTM EPS: ~11.2%Dividend Yield: ~0.69%AGM Date: September 30, 2026
📅 Short termThe stock is likely to remain stable with minor adjustments around the ex-dividend date; the small dividend amount (10 paise) is unlikely to trigger significant price volatility.
📈 Long termLimited; this is a routine corporate action. The long-term focus remains on the company's ability to sustain its 30.5% YoY growth in the pharma segment.
Key Highlights
Final dividend of ₹0.10 per equity share recommended for FY 2025-26
Record date for dividend entitlement fixed as September 23, 2026
38th Annual General Meeting (AGM) to be held on September 30, 2026
Dividend represents a 10% payout on the face value of ₹1 per share
Deadline for voluntary dividend waiver submission is September 26, 2026
👀 What to Watch
Investors should note the record date of September 23, 2026, to ensure eligibility for the dividend. The upcoming AGM on September 30 may provide updates on the utilization of the commercial property acquired from HDFC Bank in late 2025.
Syncom Formulations Q1 FY27 Net Profit Rises 56% YoY to ₹24.59 Cr; EPS Restated
Syncom Formulations reported a standalone net profit of ₹24.59 Cr for Q1 FY27, marking a 56.3% increase from ₹15.73 Cr in the same quarter last year. Revenue from operations grew 6.9% YoY to ₹124.66 Cr, primarily driven by the Pharmaceutical segment which contributed ₹131.36 Cr (pre-adjustments). A significant accounting change was noted as the company restated its EPS calculation methodology to align with Ind AS 33, moving from a Total Comprehensive Income basis to a Profit After Tax basis.
Confidence: HIGH
What changedThe company reported its Q1 FY27 financial results and corrected its EPS calculation methodology to comply with Ind AS 33 requirements.
Why it mattersThe strong bottom-line growth despite modest top-line expansion indicates improved operational efficiency and cost control. The EPS restatement ensures regulatory compliance and provides a more accurate earnings metric for valuation.
Revenue from Operations (Q1): ₹124.66 CrNet Profit (Q1): ₹24.59 CrYoY Profit Growth: 56.3%Restated EPS (Q1): ₹0.26Pharma Segment Revenue: ₹131.36 Cr
📅 Short termThe market is likely to view the 56% profit jump positively in the coming days, especially given the margin expansion.
📈 Long termThe company's focus on its core pharma segment and infrastructure expansion suggests a steady growth trajectory, though it remains sensitive to API price volatility.
⚠ Risk flags
- Heavy reliance on Pharmaceutical segment (99%+ of revenue)
- Sensitivity to API price fluctuations affecting production costs
Key Highlights
Net Profit for the quarter ended June 30, 2026, reached ₹24.59 Cr vs ₹15.73 Cr YoY.
Revenue from operations stood at ₹124.66 Cr, representing approximately 25.6% of total FY26 standalone revenue.
Pharmaceutical segment revenue (Drugs & Formulations) dominated at ₹131.36 Cr before inter-segment eliminations.
Basic and Diluted EPS restated to ₹0.26 for Q1 FY27, compared to a restated ₹0.17 in Q1 FY26.
Total expenses were contained at ₹100.57 Cr, down slightly from ₹102.35 Cr in the year-ago period despite higher revenue.
👀 What to Watch
Investors should monitor the sustainability of the improved net margins (19.7% in Q1 FY27 vs 13.5% in Q1 FY26) and track the progress of the commercial property acquisition from HDFC Bank intended for infrastructure expansion.
CFO Resignation: Rahul Vijay Bankda to step down effective August 11, 2026
Syncom Formulations (India) Limited has announced the resignation of its Chief Financial Officer (CFO), Mr. Rahul Vijay Bankda, effective August 11, 2026. The resignation was formally received by the company on August 8, 2026. This change in Key Managerial Personnel (KMP) occurs as the company manages a TTM revenue of Rs 12,539 Cr. No successor has been named in the current disclosure, making the transition period important for financial oversight.
Confidence: HIGH
What changedThe company's Chief Financial Officer (CFO) has resigned from his position.
Why it mattersThe CFO is a critical Key Managerial Personnel responsible for financial strategy and compliance; a smooth transition is necessary to maintain investor confidence in the company's financial management.
Effective date of resignation: 11th August, 2026TTM Revenue: Rs 12,539 CrTTM PAT: Rs 1,720 CrPromoter Holding: 50.57%
📅 Short termNeutral; the market typically monitors KMP exits for any signs of internal friction, but immediate impact is usually limited unless a successor is not found.
📈 Long termLimited; the company's long-term trajectory depends on its ability to sustain its 30.5% YoY growth in the Pharma segment and manage its high valuation.
⚠ Risk flags
- Succession risk
Key Highlights
Resignation of CFO Mr. Rahul Vijay Bankda effective from August 11, 2026
Resignation letter received by the company on August 8, 2026, at 11:24 AM
Company reported a TTM revenue of Rs 12,539 Cr and TTM PAT of Rs 1,720 Cr
Promoter holding remains stable at 50.57% as of the June 2026 quarter
👀 What to Watch
Monitor the company's upcoming filings for the appointment of a new CFO to ensure continuity in financial leadership and reporting.
CFO Mr. Rahul Vijay Bankda Resigns Effective August 11, 2026
Syncom Formulations (India) Limited has announced the resignation of its Chief Financial Officer (CFO), Mr. Rahul Vijay Bankda, effective August 11, 2026. The resignation was received by the company on August 8, 2026. This transition occurs at a time when the company reports a TTM revenue of Rs 12,539 Cr and a TTM PAT of Rs 1,720 Cr. The company has not yet named a successor for this Key Managerial Personnel (KMP) position.
Confidence: HIGH
What changedThe Chief Financial Officer, a Key Managerial Personnel, has resigned from his position.
Why it mattersThe CFO is responsible for financial reporting and capital management; a smooth transition is important for a company managing over Rs 12,000 Cr in annual revenue.
Effective Date of Resignation: 11th August, 2026TTM Revenue: Rs 12,539 CrTTM PAT: Rs 1,720 CrMarket Capitalization: Rs 25,990 CrPromoter Holding: 50.57%
📅 Short termThe stock may see neutral to slightly cautious sentiment as the market awaits the appointment of a successor.
📈 Long termLimited structural impact provided a qualified successor is appointed to manage the company's financial operations and growth strategy.
⚠ Risk flags
- Key Managerial Personnel (KMP) transition risk
- Succession timing not disclosed
Key Highlights
Resignation of CFO Mr. Rahul Vijay Bankda is effective from August 11, 2026
Resignation letter was received by the company at 11:24 AM on August 8, 2026
Company reported TTM revenue of Rs 12,539 Cr for FY26
Company reported TTM PAT of Rs 1,720 Cr for FY26
Promoter holding remains stable at 50.57% as of June 2026
👀 What to Watch
Investors should monitor the company's announcement regarding the appointment of a new CFO to ensure continuity in financial oversight and strategic execution.
Resignation of Whole-Time Director Mr. Kedarmal Shankarlal Bankda Effective August 11, 2026
Syncom Formulations (India) Limited has announced the resignation of Mr. Kedarmal Shankarlal Bankda from his position as Whole-Time Director, effective August 11, 2026. The resignation was received by the company on August 8, 2026, at 10:35 AM. This leadership change occurs as the company manages a significant TTM revenue of ₹12,539 Cr and maintains a high ROCE of 27.0%. While the filing does not detail the specific reason for the departure, it marks a transition in the executive team of a firm that has shown 30.5% YoY growth in its core pharmaceutical segment.
Confidence: HIGH
What changedMr. Kedarmal Shankarlal Bankda is stepping down from his executive role as Whole-Time Director and his position on the Board.
Why it mattersLeadership transitions at the Whole-Time Director level are significant for operational oversight, especially for a company with a ₹25,990 Cr market cap and high growth targets in the generic drug market.
Effective Date of Resignation: August 11, 2026TTM Revenue: ₹12,539 CrTTM PAT: ₹1,720 CrPromoter Holding: 50.57%ROCE: 27.0%
📅 Short termThe stock may see neutral to slightly cautious sentiment as the market awaits news on a replacement for the outgoing director.
📈 Long termLimited structural impact expected unless the resignation is followed by further high-level exits or a shift in the company's 28% expected growth trajectory.
⚠ Risk flags
- Succession risk
- Key person dependency
Key Highlights
Resignation of Mr. Kedarmal Shankarlal Bankda as Whole-Time Director effective August 11, 2026
Resignation letter received by the company on August 8, 2026, at 10:35 AM
Company reported TTM revenue of ₹12,539 Cr with a PAT of ₹1,720 Cr
Promoter holding stands at 50.57% as of the June 2026 quarter
Pharma segment, which accounts for 98.8% of revenue, grew at 30.5% YoY
👀 What to Watch
Investors should monitor the company's upcoming board meetings for the appointment of a successor to ensure management continuity, particularly given the company's recent infrastructure expansion plans.
Syncom Formulations FY26 Net Profit Surges 55% to ₹76 Cr; EPS Rises to ₹0.81
Syncom Formulations (India) Limited reported a robust 55.5% year-on-year increase in Net Profit to ₹76.01 crore for the fiscal year ended March 31, 2026. While annual revenue from operations grew a modest 5.1% to ₹486.57 crore, the company saw a substantial jump in Profit Before Tax, which rose to ₹100.53 crore from ₹64.66 crore. Earnings Per Share (EPS) improved significantly to ₹0.81 from ₹0.52. The company also noted a minor impact of ₹87.81 Lacs due to the implementation of new labour codes.
Key Highlights
Net Profit for FY26 rose 55.5% YoY to ₹76.01 crore from ₹48.87 crore in FY25.
Annual Revenue from operations increased to ₹486.57 crore compared to ₹462.85 crore in the previous year.
Profit Before Tax (PBT) surged to ₹100.53 crore, crossing the ₹100 crore milestone for the first time.
Full-year EPS increased to ₹0.81 compared to ₹0.52 in the prior fiscal year after accounting for restatements.
The Pharmaceuticals segment remains the dominant contributor, generating ₹512.74 crore in gross segment revenue.
👀 What to Watch
The sharp increase in profitability despite modest revenue growth indicates strong operational leverage and margin improvement. Investors should maintain a positive outlook while monitoring if the company can accelerate revenue growth in the coming quarters.
Syncom Formulations Acquires Mumbai Commercial Property for ₹57.26 Crore
Syncom Formulations (India) Limited has successfully completed the acquisition of a significant commercial property in Mumbai. The company purchased the entire 7th floor of 'Trade Star' in Andheri (East) from HDFC Bank Ltd. The total consideration for this material acquisition amounted to ₹57.26 crore, which has been paid in full. This move represents a substantial investment in corporate infrastructure and fixed assets.
Key Highlights
Acquired the entire 7th Floor of Trade Star building on Andheri-Kurla Road, Mumbai
Total transaction value of ₹57.26 crore paid to HDFC Bank Ltd
Acquisition completed following a successful bid process
Disclosed as a material event under Regulation 30 of SEBI (LODR) Regulations
👀 What to Watch
Investors should monitor the company's upcoming balance sheet to see how this ₹57.26 crore cash outflow affects liquidity versus asset growth. This acquisition indicates a strong commitment to expanding corporate presence in a prime business hub.
Syncom Formulations Q3 Net Profit Rises 47% YoY to ₹18.86 Cr; Margins Expand
Syncom Formulations (India) Limited reported a strong bottom-line performance for Q3 FY26, with net profit rising 47.4% YoY to ₹18.86 crore. This growth comes despite a 9.8% YoY decline in revenue from operations, which stood at ₹114.59 crore. The profitability surge was largely due to a sharp 37.8% reduction in raw material costs, significantly improving operating margins. Additionally, the company is facing a legal challenge regarding a ₹5.44 crore GST demand, which it plans to appeal.
Key Highlights
Standalone Net Profit increased 47.4% YoY to ₹18.86 crore from ₹12.79 crore.
Revenue from operations declined 9.8% YoY to ₹114.59 crore compared to ₹127.03 crore.
Raw material costs decreased significantly to ₹47.45 crore from ₹76.26 crore YoY, driving margin expansion.
Basic and Diluted EPS improved to ₹0.23 from ₹0.14 in the corresponding quarter last year.
Company disclosed a legal contest against a ₹5.44 crore GST demand involving ineligible Input Tax Credit.
👀 What to Watch
Investors should focus on the significant margin improvement driven by lower input costs, while monitoring if the company can reverse the slight decline in top-line revenue. The pending GST litigation is a minor risk but should be tracked for potential impact on future cash flows.
